Medications for Opioid Use Disorder in Pregnancy | Part 2

Presenter: Candy Stockton, MD, FASAM

Online CME Credit

Fee: $30.00

Provides 1.25 hour(s) of CE/CME credit (Presented on December 2-3, 2019; Reviewed August 1, 2020; Expires August 1, 2022)

Provides CME credit towards the Nevada State Board of Medical Examiners' requirement for 2 hours of training related to the misuse and abuse of controlled substances, the prescribing of opioids, or addiction during each licensure period.

Overview

Opioid use disorder (OUD) in the US continues to rise, including among women of childbearing age. Pregnant women with opioid use disorder face many barriers to care, including stigma, limited access to treatment, and fear of legal consequences. The speaker will cover the science and best practices in treating pregnant women with OUD and their infants, as well as a panel focused on case review and discussion.

Learning Objectives

Following participation in this course, participants should be able to:

  • Explain how stigma affects women's ability to access treatment for Opioid Use Disorder
    (OUD) while pregnant
  • Define the Standard of Care for the treatment of pregnant women with OUD
  • Understand the three medication options available for OUD and the evidence for each
    treatment in pregnancy
  • Develop guidelines for initiating and continuing buprenorphine treatment during pregnancy
  • Identify high-risk periods for overdose/death related to OUD
  • Discuss the role of drug testing while treating pregnant women in their own setting
  • Understand the role of Medications for Opioid Use Disorder (MOUD) in women with polysubstance use
  • Discuss legal/liability concerns related to treating pregnant women with SUD and take steps to minimize this risk
  • Recognize common signs/symptoms of Neonatal Opioid Withdrawal Syndrome (NOWS)
  • Describe the differences between traditional NAS/NOWS treatment and Eat, Sleep,
    Console Methodology